This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Bart Barlogie, MD; Raymond Alexanian, MD; Sundar Jagannath, MD

JAMA. 1992;268(20):2946-2951.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

PLASMA cell dyscrasias refer to a spectrum of disorders characterized by the monoclonal proliferation of lymphoplasmacytic cells in the bone marrow and, sometimes, tissue deposition of monoclonal immunoglobulins or their components (Table 21-1). The disorders include multiple myeloma (MM) and Waldenström's macroglobulinemia, as well as rare conditions such as light-chain deposition disease (LCDD) and heavy-chain diseases (HCDs). Amyloidosis refers to a group of tissue deposition disorders, among which light-chain amyloidosis is a plasma cell dyscrasia. Monoclonal gammopathy of undetermined significance is an asymptomatic laboratory deviation that may evolve into one of the previously mentioned diseases.

MULTIPLE MYELOMA

Multiple myeloma is the most serious and prevalent plasma cell dyscrasia, affecting approximately four of 100 000 Americans each year (Table 21-2). The median age at onset is 60 years, and black persons are affected twice as often as white persons. Symptoms usually result from lytic bone disease, anemia, renal failure, and immunodeficiency. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?